home / stock / mdwd / mdwd news

MDWD News and Press, MediWound Ltd. From 10/03/23

Stock Information
Company Name: MediWound Ltd.
Stock Symbol: MDWD
Market: NASDAQ
Website: mediwound.com
Menu
MDWD MDWD Quote MDWD Short MDWD News MDWD Articles MDWD Message Board
Get MDWD Alerts

News, Short Squeeze, Breakout and More Instantly...
MDWD - Q4 Stock Predictions: 3 Micro-Cap Stocks Ready to Skyrocket Into 2024

2023-10-03 13:20:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Jeremy Siegel’s prediction that the Federal Reserve will not raise interest rates in November, despite the pressure from higher bond yields on the equities market, holds si...
MDWD - MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army

YAVNE, Israel, Sept. 26, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced that the U.S. Department of Defense (DoD), through the Medical Technology Enterprise C...

MDWD - MediWound burn therapy NexoBrid launched in US

2023-09-21 14:15:44 ET More on MediWound Seeking Alpha’s Quant Rating on MediWound Financial information for MediWound MediWound Ltd. (MDWD) Q2 2023 Earnings Call Transcript MediWound GAAP EPS of $0.10 beats by $0.47, revenue of $4.77M beats by $0.59M ...

MDWD - MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults

YAVNE, Israel, Sept. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced the U.S. commercial availability of NexoBrid ® (anacaulase-bcdb) for the remo...
MDWD - MediWound's NexoBrid® Highlighted in 20 Oral and Poster Presentations at the 20th European Burns Association Congress

YAVNE, Israel, Sept. 11, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced its successful participation at the recently con...

MDWD - MediWound to Participate in Fireside Chat at H.C. Wainwright 25th Annual Global Investment Conference

YAVNE, Israel, Sept. 05, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced its participation in the upcoming H.C. Wainwright 25 th Annual Global Investment C...

MDWD - MediWound Ltd. (MDWD) Q2 2023 Earnings Call Transcript

2023-08-16 13:49:09 ET MediWound Ltd. (MDWD) Q2 2023 Earnings Call Transcript August 16, 2023 08:30 AM ET Company Participants Monique Kosse - LifeSci Advisors, IR Ofer Gonen - Chief Executive Officer Barry Wolfenson - Executive Vice President of Strategy & C...
MDWD - MediWound GAAP EPS of $0.10 beats by $0.47, revenue of $4.77M beats by $0.59M

2023-08-15 16:34:38 ET MediWound press release ( NASDAQ: MDWD ): Q2 GAAP EPS of $0.10 beats by $0.47 . Revenue of $4.77M (+2.1% Y/Y) beats by $0.59M . As of June 30, 2023, the Company's cash and short-term deposits were $51.3 million, compared to $34.1 million ...

MDWD - MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update

EscharEx ® Phase III study protocol : FDA/EM A-aligned ; p atient enrollment commencing early 2024 ; two key research collaborations with wound industry leaders NexoBrid ® U.S. commercial launch timing ...

MDWD - MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III Study

YAVNE, Israel, Aug. 15, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced a research collaboration agreement with Mölnlycke for its upcoming Phase III study...
Previous 10 Next 10